866-997-4948(US-Canada Toll Free)

Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market

Published By :

GBI Research

Published Date : Sep 2010

Category :

Therapeutic Area

No. of Pages : 101 Pages


GBI Research’s pharmaceuticals report, “Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market. The report analyzes the markets for hepatitis therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. 

Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. 

GBI Research finds that the global hepatitis therapeutics market is one of the growing markets of the pharmaceutical business. Due to the approval of potential new drugs as well as combinational therapies, the hepatitis market will grow further. Launch of drugs with significant efficacy, safety and resistance profiles will fuel rapid uptake of drugs in near future. 

The limitations of current standard care therapy for hepatitis due to high incidence of adverse events, long duration of treatment, suboptimal patient compliance, lack of efficacy in specific genotypes has increased interest in developing novel products that can probably counter the unmet needs presented by the present market. 

However, the market sales growth is expected to slow down marginally due to the declining hepatitis incidence rates (use of vaccines), public awareness, and patent expiries of key therapeutics. Nevertheless, the global hepatitis market is still forecasted to grow at a compound annual growth rate (CAGR) of 3.1% between 2001 and 2009.

Scope

  • Annualized market data for the hepatitis therapeutics market from 2001 to 2009, forecast forward to 2016.
  • Analysis of the leading therapeutic segments, including hepatitis A, hepatitis B and hepatitis C.
  • Analysis of the hepatitis therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.
  • Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global hepatitis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to :

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Table of Contents

1 Table of Contents 4

1.1 List of Tables 6
1.2 List of Figures 7

2 Global Hepatitis Therapeutics Market: Introduction 9
2.1 GBI Research Report Guidance 10

3 Global Hepatitis Therapeutics Market: Market Overview 11
3.1 Introduction 11
3.2 Revenue Forecasts for the Global Hepatitis Therapeutics Market 12
3.2.1 Sales Value 12
3.2.2 Treatment Usage Patterns 14
3.3 Hepatitis Market Drivers 19
3.3.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline 19
3.3.2 Promising Developments in Hepatitis C Pipeline 19
3.3.3 Steady Increase in Prescription Population 20
3.4 Hepatitis Market Restraints 20
3.4.1 Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms during Acute Phase 20
3.4.2 Low Treatment Seeking Population 20
3.4.3 Loss of Exclusivity Protection in Hepatitis B Market 20
3.5 Generic Share in the Global Hepatitis Market 21

4 Global Hepatitis Market: Therapeutic Landscape 22
4.1 Introduction 22
4.1.1 Hepatitis A 22
4.1.2 Hepatitis B 22
4.2 Overview of Hepatitis A and B Vaccines Market 23
4.2.1 Sales Value 23
4.3 Hepatitis B Market 24
4.3.1 Introduction 24
4.3.2 Sales Value 25
4.3.3 Annual Cost of Therapy 26
4.3.4 Treatment Usage Patterns 27
4.3.5 Geographical Segmentation 32
4.4 Hepatitis C Market 34
4.4.1 Introduction 34
4.4.2 Sales Value 35
4.4.3 Annual Cost of Therapy 36
4.4.4 Treatment Usage Patterns 37
4.4.5 Geographical Segmentation 42

5 Global Hepatitis Market: Geographical Landscape 45
5.1 Geographical Break-up 45
5.2 The US 48
5.2.1 Sales Value 48
5.2.2 Annual Cost of Therapy 49
5.2.3 Treatment Usage Patterns 50
5.3 Top Five Countries in Europe 55
5.3.1 Sales Value 55
5.3.2 Annual Cost of Therapy 56
5.3.3 Treatment Usage Patterns 57
5.4 Japan 62
5.4.1 Sales Value 62
5.4.2 Annual Cost of Therapy 63
5.4.3 Treatment Usage Patterns 64

6 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis 69
6.1 Introduction 69
6.1.1 Research and Development Pipeline Hepatitis B Therapeutics 71
6.1.2 Research and Development Pipeline Hepatitis C Therapeutics 72
6.2 Profiles of Key Late-Stage Vaccines in the Hepatitis A & B Market 73
6.2.1 Heplisav 73
6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development 74
6.3.1 Entecavir + Adefovir combination therapy 74
6.3.2 Truvada (Tenofovir plus Emtricitabine combination therapy) 74
6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development 75
6.4.1 Boceprevir (SCH 503034, narlaprevir) 75
6.4.2 Tenofovir + Emtricitabine Combination therapy 76
6.4.3 Zalbin (albinterferon alfa-2b, Joulferon) 76
6.4.4 Telaprevir (VX 905) 77
6.4.5 RG 7128 79

7 Global Hepatitis Vaccines & Therapeutics Market: Competitive Landscape 81
7.1 Market Share Analysis: Hepatitis 81
7.2 Competitive Profiling 82
7.2.1 Merck & Co., Inc. 82
7.2.2 F. Hoffmann-La Roche Ltd. 85
7.2.3 GlaxoSmithKline plc 87

8 Global Hepatitis Market: Strategic Consolidations 89
8.1 Mergers and Acquisitions 89
8.1.1 Overview 89
8.1.2 Summary of M&A Deals (2009-2010) 90
8.2 R&D Licensing Agreements 91
8.2.1 Summary of Licensing Deals (2009-2010) 91

9 Global Hepatitis Market: Appendix 96
9.1 Market Definitions 96
9.2 Abbreviations 96
9.3 Research Methodology 97
9.4 Research Methodology 97
9.4.1 Coverage 97
9.4.2 Secondary Research 97
9.4.3 Primary Research 98
9.4.4 Forecasts 98
9.4.5 Expert Panel Validation 100
9.5 Contact Us 101
9.6 Disclaimer 101

List of Table


Table 1: Hepatitis Therapeutics Market, Global, Sales Value ($m), 20012009 12
Table 2: Hepatitis Therapeutics Market, Global, Sales Value ($m), 20092016 12
Table 3: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20012009 13
Table 4: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20092016 13
Table 5: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 20012009 15
Table 6: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 20092016 15
Table 7: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 20012009 23
Table 8: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 20092016 23
Table 9: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 20012009 25
Table 10: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 20092016 25
Table 11: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 20012009 26
Table 12: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 20092016 26
Table 13: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (000), 20012009 27
Table 14: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (000), 20092016 28
Table 15: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 20012009 33
Table 16: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 20092016 33
Table 17: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 20012009 35
Table 18: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 20092016 35
Table 19: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 20012009 36
Table 20: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 20092016 36
Table 21: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 20012009 37
Table 22: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 20092016 38
Table 23: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 20012009 43
Table 24: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 20092016 43
Table 25: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 20012009 46
Table 26: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 20092016 46
Table 27: Hepatitis Therapeutics Market, US, Sales Value ($m), 20012009 48
Table 28: Hepatitis Therapeutics Market, US, Sales Value ($m), 20092016 48
Table 29: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 20012009 49
Table 30: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 20092016 49
Table 31: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (000), 20012009 50
Table 32: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (000), 20092016 51
Table 33: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 20012009 55
Table 34: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 20092016 55
Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 20012009 56
Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 20092016 56
Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (000), 20012009 57
Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (000s), 20092016 58
Table 39: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 20012009 62
Table 40: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 20092016 62
Table 41: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 20012009 63
Table 42: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 20092016 63
Table 43: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (000), 20012009 64
Table 44: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (000), 20092016 65
Table 45: Final Prove 3 SVR Results for Telaprevir, HCV 78

List of Chart


Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2009 11
Figure 2: Hepatitis Therapeutics Market, Global, Sales Value ($m), 20012016 12
Figure 3: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20012016 13
Figure 4: Hepatitis Therapeutics Market, Global, Therapeutic Usage Patterns, 20012016 14
Figure 5: Hepatitis Therapeutics Market, Global, Diseases Population, 20012016 16
Figure 6: Hepatitis Therapeutics Market, Global, Treatment Seeking Population, 20012016 17
Figure 7: Hepatitis Therapeutics Market, Global, Diagnosed Population, 20012016 18
Figure 8: Hepatitis Therapeutics Market, Global, Prescription Population, 20012016 19
Figure 9: Hepatitis B and Hepatitis C Therapeutic Market, Global, Branded and Generic Drugs (%), 2009 21
Figure 10: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 20012016 23
Figure 11: Hepatitis Therapeutics Market, Global, Hepatitis B-Genotypes Based on Geographic Origins 24
Figure 12: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 20012016 25
Figure 13: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 20012016 26
Figure 14: Hepatitis Market, Global, Hepatitis B Treatment Usage Patterns, 20012016 27
Figure 15: Hepatitis Market, Global, Hepatitis B Diseased Population, 20012016 28
Figure 16: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Seeking Population, 20012016 29
Figure 17: Hepatitis Market, Global, Hepatitis B Diagnosis Population, 20012016 30
Figure 18: Hepatitis Therapeutics Market, Global, Hepatitis B Prescription Population, 20012016 31
Figure 19: Hepatitis Therapeutics Market, Global, Hepatitis B Market Segmentation by Geography (%), 2009 and 2016 32
Figure 20: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 20012016 32
Figure 21: Hepatitis Therapeutics Market, Global, Hepatitis B Market, Geography Benchmarking, 2009 34
Figure 22: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 20012016 35
Figure 23: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 20012016 36
Figure 24: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 20012016 37
Figure 25: Hepatitis Therapeutics Market, Global, Hepatitis C Diseased Population, 20012016 38
Figure 26: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Seeking Population, 20012016 39
Figure 27: Hepatitis Therapeutics Market, Global, Hepatitis C Diagnosis Population, 20012016 40
Figure 28: Hepatitis Therapeutics Market, Global, Hepatitis C Prescription Population, 20012016 41
Figure 29: Hepatitis Therapeutics Market, Global, Hepatitis C Market Segmentation by Geography (%), 2009 and 2016 42
Figure 30: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation ($m), 20012016 42
Figure 31: Hepatitis Therapeutics Market, Global, Hepatitis C Market, Geography Benchmarking, 2009 44
Figure 32: Hepatitis Therapeutics Market, Global, Market Share by Geography (%), 2009 and 2016 45
Figure 33: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 20012016 46
Figure 34: Hepatitis Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016 47
Figure 35: Hepatitis Therapeutics Market, US, Sales Value ($m), 20012016 48
Figure 36: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 20012016 49
Figure 37: Hepatitis Therapeutics Market, US, Treatment Usage Patterns, 20012016 50
Figure 38: Hepatitis Therapeutics Market, US, Diseased Population, 20012016 51
Figure 39: Hepatitis Therapeutics Market, US, Treatment Seeking Population, 20012016 52
Figure 40: Hepatitis Therapeutics Market, US, Diagnosed Population, 20012016 53
Figure 41: Hepatitis Therapeutics Market, US, Prescription Population, 20012016 54
Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 20012016 55
Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 20012016 56
Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 20012016 57
Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population, 20012016 58
Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 20012016 59
Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population, 20012016 60
Figure 48: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population, 20012016 61
Figure 49: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 20012016 62
Figure 50: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 20012016 63
Figure 51: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 20012016 64
Figure 52: Hepatitis Therapeutics Market, Japan, Diseased Population, 20012016 65
Figure 53: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population, 20012016 66
Figure 54: Hepatitis Therapeutics Market, Japan, Diagnosed Population, 20012016 67
Figure 55: Hepatitis Therapeutics Market, Japan, Prescription Population, 20012016 68
Figure 56: Hepatitis Therapeutics Market, Global, R&D Pipeline by Indication (%), March 2010 69
Figure 57: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase (%), March 2010 70
Figure 58: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis B vaccines Market (%), March 2010 71
Figure 59: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis C vaccines Market (%), March 2010 72
Figure 60: Hepatitis B and Hepatitis C Therapeutics Markets, Global, Market Share of Top Manufacturers (%), 2010 81
Figure 61: Hepatitis Vaccine Market, Global, Revenue of Top Players (%), 2010 82
Figure 62: Merck & Co., Inc., SWOT Analysis, 2010 83
Figure 63: F. Hoffmann-La Roche Ltd., SWOT Analysis, 2010 85
Figure 64: GlaxoSmithKline plc, SWOT Analysis, 2010 87
Figure 65: Hepatitis Therapeutics Market, Global, M&A Deals by Geography, (%), 2010 89
Figure 66: Hepatitis Therapeutics Health Market, Global, M&A Deals by Type, (%), 2010 90
Figure 67: Hepatitis Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 2010 91
Figure 68: GBI Research Market Forecasting Model 100

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *